Printer Friendly

DURAMED REPORTS SECOND QUARTER RESULTS FOR 1992

 DURAMED REPORTS SECOND QUARTER RESULTS FOR 1992
 CINCINNATI, July 21 /PRNewswire/ -- E. Thomas Arington, chairman


and president of Duramed Pharmaceuticals, Inc. (NASDAQ: DRMD) announced today the company's operating results for the second quarter ended June 30, 1992. Net revenues and loss for the quarter were $3,262,000 and $103,000, respectively.
 Arington stated, "Our results remain on target with our expectations and we are continuing with the implementation of our recovery program."
 The following table sets forth Duramed's comparative results for the quarters ended June 30, 1992 and 1991:
 Three Months Ended
 June 30
 (In thousands except per share 1992 1991
 amounts and shares outstanding)
 Net revenue $ 3,262 $ 3,937
 Cost of goods sold 2,105 2,298
 Gross profit 1,157 1,639
 Operating expenses (net of
 contract revenue of $350,000
 for the 3 months ended
 June 30, 1992) 789 1,048
 Operating income (loss) 368 591
 Interest expense 471 522
 Net income (loss) $ (103) $ 69
 Net income (loss) per share
 of common stock $ (.02) $ .01
 Weighted average number of common
 shares outstanding 6,598,564 6,280,064
 Six Months Ended
 June 30
 (In thousands except per share 1992 1991
 amounts and shares outstanding)
 Net revenue $ 6,337 $ 5,105
 Cost of goods sold 4,079 4,298
 Gross profit 2,258 807
 Operating expenses (net of
 contract revenue of $350,000
 for the 3 months ended
 June 30, 1992) 1,889 2,502
 Operating income (loss) 369 (1,695)
 Interest expense 931 1,013
 Net income (loss) $ (562) $(2,708)
 Net income (loss) per share
 of common stock $ (.09) $ (.43)
 Weighted average number of common
 shares outstanding 6,586,314 6,280,064
 Duramed Pharmaceuticals, Inc. manufactures and sells generic drug products comprised of various dosages of prescription and over-the-counter drugs. Duramed's stock is traded under the symbol DRMD.
 -0- 7/21/92
 /CONTACT: E. Thomas Arington, chairman and chief executive officer, or Timothy J. Holt, vice-president finance, 513-731-9900, both of Duramed Pharmaceuticals/ CO: Duramed Pharmaceuticals, Inc. ST: Ohio IN: MTC SU: ERN


BM -- CL020 -- 1348 07/21/92 12:41 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 21, 1992
Words:348
Previous Article:MUTUAL FUND INDUSTRY ASSOCIATION ENDORSES MEASURE AIMED AT ATTRACTING FOREIGN INVESTMENT
Next Article:WORTHINGTON FOODS, INC. ANNOUNCES HIGHER SECOND QUARTER EARNINGS
Topics:


Related Articles
DURAMED REPORTS FIRST QUARTER RESULTS FOR 1992
DURAMED REPORTS 1992 RESULTS; REPORTS DEPARTMENT OF JUSTICE SETTLEMENT; PREDICTS PROFIT FOR FIRST QUARTER
DURAMED REPORTS PROFIT FOR FIRST QUARTER 1993
DURAMED REPORTS SECOND QUARTER RESULTS FOR 1993
DURAMED REPORTS THIRD QUARTER RESULTS FOR 1993
DURAMED REPORTS 1993 RESULTS
Duramed Pharmaceuticals Reports Second Quarter 1997 Results
Duramed Pharmaceuticals Reports Third Quarter Results.
Duramed Reports Second Quarter 2000 Profit with Record Sales.
Duramed Pharmaceuticals Reports Q3 2000 EPS of 4 Cents * Sales up 100% from third quarter 1999 * Net income at $1.1 million * Rising contribution...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters